CMD-011

N/A

Report date: 2026/05/21 20:00:22

First In Class

Base Information

Drug NameCMD-011

Drug Alias NameCMD-011CMD011CMD 011

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsGlypican-3 modulators

TargetsT cell surface glycoprotein CD3Glypican-3

Therapy Area/IndicationsLiver NeoplasmsCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesZhejiang Shimai Pharmaceutical Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZhejiang Shimai Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsLiver NeoplasmsCarcinoma, Hepatocellular

Inactive IndicationsN/A

Other Information

ATC CodeN/A